Drug Profile
Calcitonin intranasal (Calcimar) - sanofi-aventis
Alternative Names: Calcimar Intranasal; Calcitonina Almirall; CalogenLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Almirall S.A.; sanofi-aventis
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteitis deformans; Postmenopausal osteoporosis
Most Recent Events
- 20 Jul 2012 The European Medicines Agency recommended that intranasal calcitonin-containing medicines should not be used for osteoporosis. Due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 22 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma